Effects of Macular Ischemia and Early Treatment on Visual Outcome in Branch Retinal Vein Occlusion.
10.3341/jkos.2014.55.2.209
- Author:
Kyung Hoon SEO
1
;
Ji Ho YANG
;
Seung Young YU
;
Hyung Woo KWAK
Author Information
1. Department of Ophthalmology, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, Korea. hwkwak@khu.ac.kr
- Publication Type:Original Article
- Keywords:
Bevacizumab;
Branch retinal vein occlusion;
Early treatment;
Four-year results;
Macular ischemia
- MeSH:
Follow-Up Studies;
Humans;
Ischemia*;
Retinal Vein Occlusion*;
Retinal Vein*;
Retinaldehyde*;
Retrospective Studies;
Tomography, Optical Coherence;
Visual Acuity;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2014;55(2):209-215
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the effects of macular ischemia and early treatment on the visual outcomes of patients with branch retinal vein occlusion (BRVO). METHODS: This study retrospectively reviewed the records of 42 patients who were treated with an intravitreal bevacizumab injection for BRVO, repeated 3 times at 6-week intervals and were whose data available for a follow-up period of at least 4 years. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) results before treatment and at 6, 12, 24, 36 and 48 months after the 3 serial injections, were measured. We assessed macular ischemia, time to the first treatment, and the relationship of these with BCVA. RESULTS: Mean BCVA (log MAR) was significantly improved from 0.67 +/- 0.43 at baseline to 0.30 +/- 0.30 at 48 months (p < 0.001). Four years after treatment, mean BCVA in the macular non-ischemic group was better than in the ischemic group, but this relationship did not hold for mean change in BCVA. There was a statistically significant (p < 0.05) difference between the early (< or =6 weeks) and late (>6 weeks) treatment groups in BCVA and mean change in BCVA after 48 months. There was statistically significant (p < 0.05) difference between the early (< or =6 weeks) and late (>6 weeks) treatment groups with macular ischemia in BCVA after 48 months. CONCLUSIONS: In patients with BRVO, a significant visual improvement was maintained after intravitreal bevacizumab injections, despite the presence of macular ischemia. Early treatment (within 6 weeks) is more effective for maintaining and improving visual acuity. Similar results in the macular ischemia group confirmed the importance of early treatment.
